Drug Profile

HDM 1005

Alternative Names: HDM-1005

Latest Information Update: 25 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hangzhou Zhongmei Huadong Pharmaceutical
Class Antihyperglycaemics; Obesity therapies; Peptides
Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Obesity; Type 2 diabetes mellitus

Most Recent Events

18 Feb 2026 Hangzhou Zhongmei Huadong Pharmaceutical plans phase III trial (Combination therapy and Monotherapy) in China in March 2026 (SC) (NCT07417306)
17 Feb 2026 Phase-III clinical trials in Type 2 diabetes mellitus in China (SC) (NCT07394114)
14 Oct 2025 Phase-III clinical trials in Obesity in China (SC) (NCT07279194)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com